Quantitative analysis for NewAmsterdam Pharma Company N.V. (NAMS) — Health Care: AI-powered alpha score, Benjamin Graham intrinsic value, ML-based forecast, technical and fundamental signals, and insider activity.
Current Q-Score verdict: Strong Sell (23.0) (grade F). 26 signals analyzed (21 differentiated alt-data).
NAMS stock price is tracked daily for technical and fundamental analysis. The data below shows recent trading activity used in trend analysis, momentum calculation, and entry/exit signals.
| Date | High | Low | Close |
|---|---|---|---|
| 2026-04-28 | $30.96 | $27.85 | $28.72 |
| 2026-05-08 | $41.17 | $34.85 | $38.73 |
| 2026-05-20 | $36.19 | $34.00 | $35.75 |
| 2026-06-02 | $32.24 | $30.72 | $31.71 |
| 2026-06-12 | $31.52 | $30.00 | $30.40 |
| 2026-06-25 | $33.09 | $31.72 | $31.73 |
| 2026-07-08 | $37.31 | $35.02 | $35.83 |
| 2026-07-20 | $32.19 | $29.57 | $29.67 |
| 2026-07-30 | $28.72 | $26.99 | $28.46 |
| 2026-08-12 | $28.16 | $27.45 | $27.83 |
| 2026-08-24 | $27.97 | $26.67 | $26.85 |
| 2026-09-03 | $25.99 | $25.24 | $25.85 |
How NewAmsterdam Pharma Company N.V. stacks up against same-sector peers on market capitalization and alpha scores:
| Ticker | Company | Market Cap | Alpha Score |
|---|---|---|---|
| HNGE | Hinge Health, Inc. | $4.2B | — |
| KNSA | Kiniksa Pharmaceuticals, Ltd. | $4.1B | — |
| MANE | Veradermics, Incorporated | $4.4B | — |
| BLLN | BillionToOne, Inc. | $3.8B | — |
View all Health Care stocks by valuation and signals →
NewAmsterdam Pharma Company N.V. (NAMS) scores Strong Sell (23.0), and the composite conceals a 80-point disagreement between its dimensions. It is strongest on competitive moat at 97 and analyst consensus at 88, and weakest on technicals at 17. A stock can carry competitive moat that high while technicals sits at 17; the composite averages that tension away, which is why the breakdown is worth reading before the headline number. See Q-Score methodology for how these dimensions are weighted and combined.
| Dimension | Score |
|---|---|
| competitive moat | 97 |
| analyst consensus | 88 |
| technicals | 17 |
StoQuant analyzes 26 signals (21 alt-data). Alternative data sources (FDA approvals, GitHub activity, SEC filings, App Store ratings) complement traditional financial metrics.
All StoQuant signals are explained in our knowledge base:
Health Care Hub — Top performers and valuation outliers in Health Care
Get daily updates on NewAmsterdam Pharma Company N.V. (NAMS): Q-Score changes, insider transactions, forecast shifts, sector rotation, and macroeconomic context. The StoQuant digest curates the most material signals for your watchlist — free, no account required.
See a sample digest • Unsubscribe anytime • Privacy policy
StoQuant is a quantitative stock research platform powered by AI scoring, fundamental analysis, and institutional-grade signals. We cover 3,600+ US-listed equities with daily updates on valuations, earnings quality, insider flow, and ML-based return forecasts. Learn more about us.
Share this stock's latest Q-Score and alpha score on your website, GitHub README, or blog. The SVG badge auto-updates daily:
<a href="https://stoquant.com/research/NAMS"><img src="https://stoquant.com/badge/NAMS.svg" alt="NewAmsterdam Pharma Company N.V. (NAMS) Q-Score and Alpha on StoQuant" width="240" height="64" /></a>
StoQuant research is generated algorithmically using public market data, SEC filings, news feeds, and proprietary ML models. Not investment advice. Past performance does not guarantee future results.
Weekly Q-Score signals and insider buying activity on our highest-conviction stock picks. Email only, no account needed. See a sample digest.